C12N 5/0635
B lymphocytes
Official title: {B lymphocytes}
C12N5/0635 (B lymphocytes) appears on 267 US grants and 596 published applications in this corpus.
Search patents in C12N- Granted patents
- 267
- Published applications
- 596
- Assignees
- 325
- Inventors
- 1,177
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 1 | 4 |
| 2003 | 2 | 8 |
| 2004 | 1 | 6 |
| 2005 | 4 | 6 |
| 2006 | 3 | 9 |
| 2007 | 3 | 11 |
| 2008 | 3 | 7 |
| 2009 | 2 | 6 |
| 2010 | 7 | 16 |
| 2011 | 5 | 11 |
| 2012 | 4 | 14 |
| 2013 | 2 | 14 |
| 2014 | 13 | 12 |
| 2015 | 11 | 18 |
| 2016 | 16 | 24 |
| 2017 | 16 | 26 |
| 2018 | 8 | 29 |
| 2019 | 14 | 55 |
| 2020 | 17 | 38 |
| 2021 | 21 | 40 |
| 2022 | 19 | 57 |
| 2023 | 19 | 42 |
| 2024 | 23 | 61 |
| 2025 | 15 | 44 |
| 2026 | 22 | 38 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for reducing elevated glucose levels11 Aug 2026US 12,703,856 B2SDF BioPharma Inc.
- B-cell cultivation method4 Aug 2026US 12,698,474 B2Hoffmann-La Roche Inc.
- Treatment with tumor infiltrating lymphocyte therapies in combination with CTLA-4 and PD-1 inhibitors14 Jul 2026US 12,678,499 B2Iovance Biotherapeutics, Inc.
- Immune cells derived from induced pluripotent stem cell14 Jul 2026US 12,680,075 B2Children's Medical Center Corporation
- Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion7 Jul 2026US 12,673,982 B2Iovance Biotherapeutics, Inc.
- Chimeric engulfment receptor molecules and methods of use8 Oct 2026US 2026/0308281 A1Cero Therapeutics Holdings, Inc.
- Lymphoid tissues with switchable protein gradients8 Oct 2026US 2026/0308498 A1Georgia Tech Research Corporation
- Treatment of autoimmune disorders using chimeric antigen receptor therapy1 Oct 2026US 2026/0295043 A1Novartis AG
- Single b-cell cultivation method24 Sep 2026US 2026/0285949 A1Hoffmann-La Roche Inc.
- Engineered cell preparations for treatment of hemophilia24 Sep 2026US 2026/0286298 A1Be Biopharma, Inc.
Most cited
By later US patents
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Simultaneous stimulation and concentration of cells383US 6,905,874 B2XCYTE Therapies, Inc. · 2005
- Transgenic transchromosomal rodents for making human antibodies195US 7,041,870 B2Kirin Brewery Co., Ltd. · 2006
- Embryonic cell populations and methods to isolate such populations111US 5,914,268 ANational Jewish Center for Immunology and Respiratory Medicine · 1999